Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VN-0200 Phase 2 Study in Japanese Healthy Elderly
NCT05547087Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VAGA-9001a + MABH-9002b in respiratory syncytial virus infection (RSV) (10 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Geometric Mean Titer of Anti-RSV Subgroup A Neutralizing Activity at Day 57 and Geometric Mean Fold Rise of Anti-RSV Subgroup A Neutralizing Activity at Day 57. Started Oct 2022; status: completed.
02
Drugs
VAGA-9001a + MABH-9002b
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05547087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547087.